ASM Microbe 2016: Switching from Tenofovir DF to TAF Improves Bone and Kidney Safety
- Details
- Category: HIV Treatment
- Published on Sunday, 10 July 2016 00:00
- Written by Liz Highleyman
People with HIV who switched from the older tenofovir disoproxil fumarate (TDF) formulation to tenofovir alafenamide (TAF) were more likely to maintain viral load suppression and showed improvements in bone density and kidney function biomarkers, according studies presented at the 2016 ASM Microbe conference last month in Boston.
ASM Microbe 2016: New Integrase Inhibitor Bictegravir Looks Promising in Early Studies
- Details
- Category: HIV Treatment
- Published on Monday, 04 July 2016 00:00
- Written by Liz Highleyman
Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favorable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity in laboratory and human studies, according to a set of posters presented at ASM Microbe 2016 last month in Boston.
ASM Microbe 2016: HIV Seroconversion Is Rare If PrEP Is Used Consistently
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 30 June 2016 00:00
- Written by Liz Highleyman
New HIV infections occurred at a low rate of about 1 per 100 person-years among people who took Truvada for pre-exposure prophylaxis (PrEP), with seroconversions mostly seen in those who stopped taking their pills, according to an analysis of more than 30 studies and demonstration projects presented last week at the ASM Microbe 2016 conference in Boston.
Coverage of ASM Microbe 2016 (ICAAC 2016)
- Details
- Category: HIV Treatment
- Published on Friday, 01 July 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of ASM Microbe 2016 -- a new conference incorporating the American Society for Microbiology annual meeting and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) -- Boston, June 16-20, 2016.
Highlights of this year's conference include antiretroviral drugs and treatment strategies, HIV pre-exposure prophylaxis (PrEP), microbiome research, antibiotic resistance, and emerging viruses including Zika.
Full coverage listing by topic
7/1/16
ASM Microbe 2016: Atripla 3 Times Weekly Maintains HIV Viral Suppression
- Details
- Category: HIV Treatment
- Published on Wednesday, 29 June 2016 00:00
- Written by Liz Highleyman
People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for 6 months, and longer follow-up is planned, according to research presented last week at the ASM Microbe conference in Boston.
Web Design and Development by